Economic burden of resected squamous cell carcinoma of the head and neck in an incident cohort of patients in the UK

Head and neck cancer (HNC) is a group of biologically similar cancers originating from the upper aerodigestive tract at various sites including the lips, oral cavity, nasal cavity, salivary glands, paranasal sinuses, thyroid, pharynx, and larynx. In the last 10 years, HNC has been one of the 10 most frequently diagnosed malignancies worldwide, with more than 640,000 people diagnosed and causing 7,500 deaths yearly [1]. In the UK, 7,538 people were newly diagnosed with HNC in 2006 and 2,594 people died from the disease in 2007 [2]. Recent trend studies reported that the incidence of HNC has risen over the last 20 years in the UK [3–7]. One of the findings showed that the incidence rate of oral and oropharyngeal cancer rose from 6.5 to 8.3 per 100,000 men and from 2.6 to 3.6 per 100,000 women between 1990--1999 [3]. According to a study of mortality in oral cancer in Europe, the age adjusted mortality rate in England and Wales was 2.7 and 1.05 per 100,000 inhabitants in men and women respectively and in Scotland the age adjusted mortality rate was 4.6 and 1.6 per 100,000 inhabitants in men and women, respectively between 1995--1999 [8]. In a projection of major cancers in the UK during 2006-2025, the mortality rate for oral cancer was estimated to still be growing in men and to be nearly constant in women [9].

The treatment of squamous cell carcinoma of the head and neck (SCCHN) is complex, partly because of the variety of tumor subsites and also because of the anatomic constraints of the head and neck region, together with the importance of maintaining organ function. Approximately 30--40% of patients with SCCHN present an early stage disease which is commonly managed by surgery (referred to as resection) or adjuvant radiotherapy with curative intent. For patients with advanced locoregionally disease without distant metastases, combinations of surgery, radiotherapy, and chemotherapy are used with the objective to maximize cure and maintain functional status through organ preservation. For patients with unresectable SCCHN, concurrent chemoradiotherapy is often chosen as a palliative treatment and may result in improved survival.

Although therapeutic advances have expanded treatment options, surgical resection is still considered an important treatment modality for SCCHN. The traditional treatment modality with surgical resection has a poor prognosis, 10--15% risk for local disease recurrence and 20--30% risk for disease progression within one year of treatment. According to a population-based study in Denmark, 1-year relative survival of patients with oral and pharynx cancer was 70% and 73% and the 5-year relative survival was 33% and 42% in men and women respectively [10]. Besides, surgery for oral cavity and oropharynx cancer was found to immediately cause impairment in physical, emotional and social functions and severely compromise the patient's quality of life (QoL) [11]. Overall QoL scores of patients with SCCHN were significantly worse at 3 and 6 months and returned to around preoperative scores at 12 months after treatment [12, 13]. However, the patients with oral cancer, who were treated with surgery, did not restore preoperational level of function in appearance, swallowing, recreation, and chewing [14–16] and no significant overall improvement was found at 12 months among patients who underwent free-flap surgery or total laryngectomy [17–22]. Finally, the treatment is burdensome on those who survive. According to findings from registry data among SCCHN patients after treatment, 55% patients had a feeding tube placed, 13% needed a tracheotomy, 79% required opioid analgesics, and 78% had anti-emetics prescribed, and 34% reported grade 3--4 mucositis/stomatitis [23].

Despite the apparent impact of the disease on patients and presumably on society and health care, the economic burden of the treatment of resected SCCHN patients in the UK has not been investigated. Therefore, this study aimed at identifying the post-operative healthcare utilisation and its associated cost for an incident cohort of patients with SCCHN in the UK who underwent surgical resection.

A retrospective analysis was performed by using Hospital Episode Statistic (HES) data, which covers all National Health Service (NHS) trusts and independent sectors in the UK. The scope of the data included secondary care facilities such as care trusts, mental health trust, NHS trust, ambulance trusts and emergency and urgent care but it did not include primary care facilities such as NHS direct/clinic centers, GP practices, dentists, opticians and pharmacists and also did not include accident and emergency care. The NHS data quality report concluded that HES data was a reliable source for activity-based analyses at national level in a provider's perspective based on high levels of completeness and validity for most fields related to patient identification in both inpatient and outpatient care [24]. However, the HES accident and emergency data still needs to be attested with reliability of the data [25] so it was not used in this analysis. The healthcare utilisation for patients in the HES data was identified with OPCS-4.5 codes which stores up individual procedures and interventions provided from inpatient and outpatient care. Mortality data between 2003 and 2009, provided by the Office for National Statistics (ONS), was used to identify deceased patients in the HES data. The requested data from HES and ONS were anonymized records, thus no patient's identity were disclosed for the purposes of this analysis.

The HES data was extracted from April 1, 2003 to March 31, 2009 and the data included patients who met the following inclusion criteria; evidence of cancer as primary diagnosis in lip, tongue, oral cavity, pharynx or larynx (ICD-10: C00--6, C09--10, C12--4, C32) and evidence of surgical resection from July 1, 2003 to March 31, 2008. The surgical resection was defined as including incision, excision, removal of foreign body, extirpation or -ectomy in respiratory tract, mouth, skin, soft tissue or bones and joints of skull of the patients. The selected patients were followed from the earliest date (index date) with the procedure code for primary surgical resection for at least 12 months or to the date of death or at the latest March 31, 2009. Patients who underwent resection between April 1, 2003 and June 30, 2003 were excluded to ensure that the patient would not be followed from a secondary resection. Patients under the age of 18 years were excluded. Figure 1 depicts the study observation period.

Post-operative healthcare utilization included the number of days of hospitalisation, the number of visits in outpatient care and treatments for chemotherapy-related adverse events. The chemotherapy-related treatments were identified by an episode of disease including anemia, neutropenia, thrombocytopenia, nausea, mucositis and pain rather than a specific treatment. The post-operative healthcare utilization also included the number of radiotherapy and chemotherapy sessions and secondary or reconstructive surgeries after resection. The secondary surgery was defined as resection following a primary resection. The reconstructive resection was defined as including plasty, plastic repair, reconstruction, and flap in respiratory tract, mouth, skin, soft tissue or bones and joints of skull of the patients.

The post-operative healthcare cost was measured by mapping the healthcare utilization to "the national schedule of reference costs 2008--09 for NHS Trusts" and "Unit costs of health & social care 2009" published by the Personal Social Services Research Unit (PSSRU). The unit costs for each procedure from inpatient and outpatient care are described in Additional file 1.

To account for the censored patients due to different lengths of follow-up in the data, the Kaplan-Meier sample-average (KMSA) method was employed. The KMSA is a technique to provide a consistent estimator of costs in the presence of censoring in the sample population[26]. The follow-up period was divided into each year and the mean cost of all uncensored patients during the each year was multiplied by the Kaplan-Meier estimate of the proportion alive at the beginning of the each year. Summing across these weighted costs for each interval resulted in the adjusted costs for censoring. The healthcare utilization and its costs were calculated in the first, second, third, fourth and fifth year from resection. The utilization and costs were to be interpreted as per year in the follow-up period for a group of the patients (incident cases) who were followed more than 1 year and less than 5 years.

The findings in the analysis were based on a large cohort of patients who were resected for SCCHN between 2003 and 2009. The patient group seemed representative of the resected SCCHN population in the UK. Rogers et al., estimated a 5 year survival rate by the Kaplan-Meier survival analyses among patients who underwent primary surgery for oral cancer during 1992--2002 in the UK [29]. Among the patients during 2000--2 in the study, overall survival rates at 2 year and 5 year were 74% and 64%, respectively. In the study cohort, overall survival rates at 2 year and 5 year were 74.0% and 64.9%, respectively, and among the resected oral cancer patients (tongue and oral cavity cancer only), overall survival rates at 2 year and 5 year were 74.2% and 65.7%, respectively. According to a comparative report of Scottish and English cohorts, a treatment modality involving surgery for HNC treatment accounted for 51.3% and 51.6% in both cohorts [30]. Among the 38,460 patients with SCCHN extracted from HES data, 14,764 patients (38.4%) of them were identified to undergo resection. The difference might be caused by miscellaneous surgeries such as biopsy that was not regarded as surgical resection in the sample selection.

In 2001, van Agthoven reported that the average cost per patient was €21,858 for HNC and €27,629 for the recurrent disease for two years in the Netherlands[31]. Based on 36% of the relapse rate from a prospective cohort study of patients with SCCHN [32], the weighted average cost would be €23,936 and it could be converted to £23,066 in 2009 (1 Euro = 0.89 GBP) [33]. It was comparable to sum of mean cost per first and second year in the results which was £21,255. Another study reported that the cost of a major head and neck surgical case was £32,000 in the UK in 2007, including inpatient cost, resection/reconstructive surgery and also nursing cost, intensive therapy unit, rehabilitation and support service cost which were not included in this analysis [34].

One of the methodological difficulties of using the HES data was that the outpatient care records had limited levels of completeness in procedural and diagnostic recording. Healthcare providers in the UK are required to submit their patient's records to NHS on a regular basis. Mandatory fields in the data submission such as patient identification details and specialty of outpatient care typically achieved a high level of completeness but optional fields still needed to be improved [24]. According to the HES outpatient data quality report [35], 97% of primary diagnosis were recorded as unknown and 93% of the main procedure/intervention was recorded as "not known" from the outpatient record in 2006--07. Thus, outpatient visit for radiotherapy and chemotherapy might be underestimated where "not known" was recorded for radiotherapy and chemotherapy-related procedures. On the other hand, the mean number of outpatient visit per year seemed to be consistent with other studies. According to a recent study of the trend of follow-up for patients with HNC in the UK, the number of follow-up appointments for patients were reported to once every 3--6 months in the third year and once every 6--12 months in the fourth and fifth year [36] and the findings were similar with the frequency of the outpatient visit identified in the sample population.

This retrospective data analysis was performed and based on a large number of empirical patient records from in- and outpatient care, and the study population seemed to be representative for resected SCCHN patients in the UK. Almost 38% of SCCHN patients underwent surgical resection and the resected patients had a high mortality rate. The patients with SCCHN needed considerable healthcare resources after surgical resection, associated with substantial costs. Over the 5-year follow-up period, 85% of costs occurred in the first year following the first surgical resection. Since outpatient-based radiotherapy and chemotherapy utilisation seemed to be underestimated, the outpatient cost of post-operative healthcare utilisation was likely to be even higher. Nevertheless, the average total cost of post-operative healthcare utilisation appeared to be comparable to previous studies.

These findings might provide a useful source for clinicians and decision makers in understanding the economic burden of managing SCCHN in the UK and also suggests a need for new therapies that could improve outcomes and reduce the disease burden.